174152-11-5

Basic information

• Product Name: (S)-2-amino-3-(4-(trifluoromethyl)phenyl)propanoic acid methyl ester
• Synonyms: (S)-2-amino-3-(4-(trifluoromethyl)phenyl)propanoic acid methyl ester
• CAS NO: 174152-11-5
• Molecular Weight: 247.217
• Mol File: 174152-11-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (S)-2-amino-3-(4-(trifluoromethyl)phenyl)propanoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-amino-3-(4-(trifluoromethyl)phenyl)propanoic acid methyl ester(174152-11-5)
• EPA Substance Registry System: (S)-2-amino-3-(4-(trifluoromethyl)phenyl)propanoic acid methyl ester(174152-11-5)

Safety Data

• Hazardous Substances Data: 174152-11-5(Hazardous Substances Data)

Upstream product

• 455-13-0 4-Iodobenzotrifluoride 
• 67-56-1 methanol 
• 3832-75-5 (S)-4-trifluoromethylphenylalanine 

Downstream Products

• 886758-83-4 (S)-2-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid methyl ester 
• 1071476-03-3 (S)-methyl 2-((S)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate 
• 178413-83-7 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propanoate 
• 1071476-61-3 (S)-methyl 2-((S)-2-(4-((2-(N-(bis(4-methoxyphenylxphenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(tert-butoxycarbonyl)-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate 
• 1613289-76-1 dimethyl 3,4-bis(4-(trifluoromethyl)phenyl)-1H-pyrrole-2,5-dicarboxylate 
• 886758-85-6 {(S)-1-[(S)-1-Carbamoyl-2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester 
• 3832-75-5 (S)-4-trifluoromethylphenylalanine 

Relevant articles and documents

Synthesis and application of peptide borate compounds

The invention belongs to the field of drug synthesis, and specifically relates to a series of novel peptide borate compounds or pharmaceutical salts thereof, and a preparation method and pharmaceutical application thereof. The structure of the peptide borate compounds or the pharmaceutical salts thereof is as shown in a formula I which is described in the specification. The compounds of the invention can be used for preparing proteasome inhibitors, and thus can be further used for treating solid tumors and blood tumors.

TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS

A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from the group consisiting of H, halo, C1-4 alkoxy, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH-C1-4 alkyl and cyano; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2e is H or Me; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl; wherein when R2e is H, at least one of R1a, R1b, R1c and R1d is selected from C1-4 alkoxy, C2-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH-C1-4 alkyl and cyano.

Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.